Effect of the Lipoxin Receptor Agonist BML-111 on Cigarette Smoke Extract-Induced Macrophage Polarization and Inflammation in RAW264.7 Cells
En Cao,Jun Xu,Yuanqi Gong,Jingjing Yuan,Anbang Chen,Jiayi Liu,Yunfei Fan,Xiangyang Fan,Xiaodong Kuang
DOI: https://doi.org/10.2147/COPD.S395569
2023-05-19
International Journal of COPD
Abstract:En Cao, 1, &ast Jun Xu, 1, &ast Yuanqi Gong, 2, &ast Jingjing Yuan, 3 Anbang Chen, 1 Jiayi Liu, 4 Yunfei Fan, 4 Xiangyang Fan, 4 Xiaodong Kuang 1 1 Department of Pathology, Basic Medical College of Nanchang University, Nanchang, Jiangxi, People's Republic of China; 2 Department of Critical Care Medicine/ICU (Intensive Care Unit), Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China; 3 Department of Physiology, School of Basic Medicine, Nanchang University, Nanchang, Jiangxi, People's Republic of China; 4 The Basic Medical School of Nanchang University, Nanchang, Jiangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaodong Kuang, Department of Pathology, Basic Medical College of Nanchang University, Nanchang, Jiangxi, People's Republic of China, Email Background: Macrophages are known to play a crucial role in the chronic inflammation associated with Chronic Obstructive Pulmonary Disease (COPD). BML-111, acting as a lipoxin A4 (LXA4) receptor agonist, has shown to be effective in protecting against COPD. However, the precise mechanism by which BML-111 exerts its protective effect remains unclear. Methods: In order to establish a cell model of inflammation, cigarette smoke extract (CSE) was used on the RAW264.7 cell line. Afterwards, an Enzyme-linked immunosorbent assay (ELISA) kit was employed to measure concentrations of tumor necrosis factor-α (TNF-α), interleukin-1beta (IL-1β), interleukin-18 (IL-18), and interleukin-10 (IL-10) in the cell supernatants of the RAW264.7 cells.In this study, we examined the markers of macrophage polarization using two methods: quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis. Additionally, we detected the expression of Notch-1 and Hes-1 through Western blotting. Results: BML-111 effectively suppressed the expression of pro-inflammatory cytokines TNF-α, IL-1β, and IL-18, as well as inflammasome factors NLRP3 and Caspase-1, while simultaneously up-regulating the expression of the anti-inflammatory cytokine IL-10 induced by CSE. Moreover, BML-111 reduced the expression of iNOS, which is associated with M1 macrophage polarization, and increased the expression of Arg-1, which is associated with M2 phenotype. Additionally, BML-111 downregulated the expression of Hes-1 and the ratio of activated Notch-1 to Notch-1 induced by CSE. The effect of BML-111 on inflammation and macrophage polarization was reversed upon administration of the Notch-1 signaling pathway agonist Jagged1. Conclusion: BML-111 has the potential to suppress inflammation and modulate M1/M2 macrophage polarization in RAW264.7 cells. The underlying mechanism may involve the Notch-1 signaling pathway. Keywords: BML-111, macrophage polarization, Notch-1 signaling pathway, COPD Chronic obstructive pulmonary disease (COPD) is defined as a common, preventable and treatable disease characterised by persistent respiratory symptoms and airflow limitation due to airway or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. 1 COPD is a leading cause of morbidity and mortality worldwide, ranked third among the leading causes of death globally in 2019. 2 In 2016, the estimated global prevalence of COPD was 251 million cases; with a population of 1397 million in China, the estimated prevalence would suggest between 113 and 187 million of the global cases being in China. 3 A number of 910,809 deaths due to COPD occurred in China in 2013, which accounted for about one-third of COPD-related deaths in the world. 4 Even worse, it is projected to affect more people in the next decade due to the ageing population and increasing exposure to risk factors. 5 Current treatments for COPD are mostly symptomatic and have limited efficacy. Research has revealed that COPD is a complex pulmonary inflammatory disease with multiple underlying causes, indicating that anti-inflammatory therapy should be a primary approach for managing COPD. Therefore, there is a need for more effective anti-inflammatory drugs to improve the treatment outcomes of COPD. 6,7 Lipoxins (LXs) are known to possess potent anti-inflammatory properties by inhibiting the release of pro-inflammatory mediators. 8 Among the various LXs, Lipoxin A4 (LXA4) has been found to bind with its receptor, a G protein-coupled receptor, also known as formyl peptide receptor 2 (FPR-2), to exert its anti-inflammatory effects. 9–11 BML-111 is a stable and potent FPR-2 agonist that -Abstract Truncated-
respiratory system